GlycanAge

Overview

GlycanAge is the only major consumer biological age test using glycan biomarkers instead of DNA methylation — founded 2019 in Newcastle upon Tyne UK, with a methodology fundamentally different from every other major biological-age test in the consumer market. Where TruDiagnostic, Elysium, and MyDNAge measure DNA methylation patterns to estimate biological age, GlycanAge measures IgG glycosylation patterns — sugars attached to immune-system antibodies that change with age, inflammation, and lifestyle.

The structural value claim is genuinely distinctive: GlycanAge measures immune-system biological age via inflammatory aging signal rather than epigenetic age. This is a different biomarker class with different clinical implications:

• Epigenetic age (TruDiagnostic, Elysium): measures cumulative DNA methylation drift; slow-moving signal that responds to interventions over months-to-years
• Glycan age (GlycanAge): measures inflammatory immune-system aging; faster-moving signal that responds to interventions over weeks-to-months

For users tracking lifestyle-intervention impact (diet, exercise, stress reduction, supplement protocols), GlycanAge’s faster-response biomarker provides more actionable feedback than epigenetic clocks. For users tracking long-horizon longevity protocols, epigenetic clocks are structurally more validated.

The structural editorial caveats: single-biomarker-class methodology lacks the depth of multi-clock epigenetic panels, UK-based fulfillment may have longer US shipping, and $348–599 pricing is premium for a single-biomarker test. For users who want a complementary signal alongside epigenetic testing, GlycanAge fills a unique role. For users who want a standalone biological-age test, the methodology trade-offs require careful consideration.

What We Measured

Note: This review is based on GlycanAge’s published IgG glycosylation methodology, Newcastle University academic-research origin, included physician consultation documentation, finger-prick collection workflow, Trustpilot review base (~100 reviews at 4.0 aggregate), and aggregated user reports. Hands-on testing of the collection experience and physician consultation depth is pending.

The IgG glycan biomarker methodology

This is the central technical differentiator. GlycanAge measures N-glycan structures attached to immunoglobulin G (IgG) antibodies in blood. The methodology measures:

• Galactosylation patterns (G0, G1, G2 structures): correlate with inflammation
• Sialylation patterns: correlate with anti-inflammatory regulation
• Bisecting N-acetylglucosamine: correlates with chronic inflammatory state
• Fucosylation patterns: additional aging-relevant glycosylation marker

The composite “glycan age” score reflects the inflammatory immune-system aging state. Higher glycan age = more pro-inflammatory glycosylation patterns = accelerated immune aging.

For comparison:

• Epigenetic clocks (TruDiagnostic, Elysium): measure DNA methylation at age-correlated CpG sites
• Telomere-length tests: measure cellular replicative aging
• GlycanAge: measures inflammatory immune-aging via IgG glycosylation

These are different biomarker classes measuring different aspects of biological aging. None is “the right” measure of biological age — they capture different dimensions of the underlying aging process.

The Newcastle University academic-research origin

GlycanAge originates from Newcastle University research on glycan biomarkers and aging. The company has continued academic-research collaborations and published validation studies in peer-reviewed journals.

The honest editorial framing: single-institution research origin is meaningful but narrower than TruDiagnostic’s Yale / Harvard partnerships or Elysium’s Yale / Morgan Levine collaboration. GlycanAge’s research depth in glycan-specific biology is strong; the breadth of academic backing is narrower than multi-institution epigenetic-clock developers.

The faster-response biomarker advantage

This is the central practical value claim. Glycan age responds to interventions on a weeks-to-months timeline vs epigenetic clocks’ months-to-years timeline. Practical implications:

• Lifestyle changes (diet, exercise, stress reduction): glycan age can show measurable change within 3–6 months
• Anti-inflammatory protocols: glycan age provides direct feedback on inflammation reduction
• Long-term longevity interventions: epigenetic clocks are structurally better at this horizon

For users running active intervention protocols and wanting feedback on protocol efficacy, GlycanAge’s faster biomarker is genuinely valuable. For users running long-term longevity bets and wanting cumulative biological-age tracking, epigenetic clocks are structurally better.

The honest framing: the “faster response” claim is well-validated for inflammatory protocols specifically, less well-validated for general lifestyle change. Buyers should weight whether their interventions specifically target inflammatory pathways before assuming the faster-response advantage applies to their use case.

The included physician consultation

Every GlycanAge package includes a 30-minute 1-on-1 physician consultation for results interpretation. This is structurally valuable:

• Inflammatory aging interpretation requires clinical context (autoimmune conditions, chronic infections, lifestyle factors)
• Intervention recommendations based on glycan results
• Comparison with other biomarkers if available

For comparison: TruDiagnostic doesn’t include physician consultation by default; Elysium provides AI-driven recommendations only; MyDNAge provides report-only. GlycanAge’s included consultation is structurally differentiated.

The single-biomarker-class limitation

This is the central structural caveat. GlycanAge measures only glycan biomarkers — no DNA methylation, no telomere length, no organ-system biological ages. Compare:

• TruDiagnostic TruAge: 950k CpG methylation sites + multi-clock approach + 11 organ-system ages
• Elysium Index: ~100k CpG methylation + 10 aging dimensions
• MyDNAge: epigenetic methylation analysis
• GlycanAge: IgG glycan profile only

For users wanting comprehensive multi-dimensional aging assessment, GlycanAge alone is incomplete. The structural recommendation: pair GlycanAge with TruDiagnostic or Elysium for complementary signal across glycan + epigenetic methodologies.

The $348–599 pricing structure

GlycanAge offers tiered pricing:

• Single test: ~$348
• Annual retest package: ~$599 (includes 2 tests + consultations)
• Payment plan: ~$29/month equivalent

For comparison: TruDiagnostic ($399–799), Elysium Index ($299), MyDNAge (~$299), InsideTracker InnerAge ($99 standalone).

GlycanAge’s pricing is mid-premium in the bio-age testing market. The included physician consultation justifies some of the premium vs report-only competitors. The single-biomarker-class methodology means buyers are paying premium pricing for narrower data than multi-clock alternatives.

3-Year Cost of Ownership

Use case	Cost
Single test	~$348
Annual retest (track intervention impact)	~$1,044 / 3 yr
Quarterly retest (active intervention monitoring)	~$4,176 / 3 yr

Compare: TruDiagnostic ($399–799 per test), Elysium Index ($299 per test), MyDNAge ($299 per test), InsideTracker InnerAge ($99 add-on).

GlycanAge’s pricing is competitive within the bio-age testing premium tier. For active-intervention monitoring (where the faster biomarker advantage is most valuable), the quarterly-retest cost compounds quickly.

Regulatory Status

CE-Marked (EU MDR), Not FDA-Cleared. GlycanAge operates under EU regulatory framework. The biological-age industry as a whole operates under wellness-tier positioning — no FDA clearance for biological-age claims is currently feasible regardless of methodology.

When GlycanAge Makes Sense — And When It Doesn’t

Strong fit:

• You’re running anti-inflammatory protocols and want fast feedback on protocol efficacy
• You want complementary signal alongside epigenetic testing (TruDiagnostic, Elysium)
• You value included physician consultation for results interpretation
• You’re making active lifestyle interventions and want measurable progress on weeks-to-months timeline
• You want finger-prick at-home collection rather than venous draw

Weaker fit:

• You want comprehensive multi-dimensional aging assessment — TruDiagnostic’s 950k CpG + 11 organ ages is structurally better
• You want established epigenetic methodology — TruDiagnostic, Elysium, MyDNAge are structurally better validated
• You’re US-based and want fastest fulfillment — UK-based shipping has friction
• You want lowest-cost biological age entry — Elysium ($299) or InsideTracker InnerAge ($99 add-on) are cheaper
• You want app-based experience — GlycanAge is web-only

Verdict: Recommended

GlycanAge earns a recommended verdict on the strength of its category-unique IgG glycan biomarker methodology (only major consumer biological age test using this approach), faster-response signal vs epigenetic clocks for active intervention monitoring, included 30-minute physician consultation providing clinical interpretation, finger-prick at-home collection eliminating lab-visit friction, and Newcastle University academic-research origin with peer-reviewed validation publications.

For users running anti-inflammatory protocols who want fast biomarker feedback on intervention efficacy, GlycanAge is structurally the leading choice in the consumer market. The faster-response timeline + inflammation-specific signal + physician interpretation combination is unique.

For users seeking comprehensive multi-dimensional aging assessment, established epigenetic methodology, fastest US fulfillment, lowest entry pricing, or app-based experience, TruDiagnostic, Elysium Index, MyDNAge, or InsideTracker InnerAge are structurally better matches respectively. GlycanAge is the specialized inflammation-focused complement to standard epigenetic testing — not a standalone replacement for comprehensive bio-age tracking.

The structural editorial recommendation: pair GlycanAge with TruDiagnostic or Elysium for complementary signals across glycan and epigenetic methodologies. The combination provides materially more aging-process insight than either methodology alone.

Changelog

• 2026-05-06: Initial review published based on GlycanAge’s published IgG glycan methodology, Newcastle University research origin, physician consultation documentation, Trustpilot review aggregation (~100 reviews at 4.0), and aggregated user-report data.